{"pmid":32434770,"title":"Predictive molecular pathology in the time of COVID-19.","text":["Predictive molecular pathology in the time of COVID-19.","AIMS: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified. METHODS: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown. RESULTS: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of euro98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (euro95-euro136) and a faster mean turnaround time (5.3 vs 7.9 working days). CONCLUSION: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed.","J Clin Pathol","Malapelle, Umberto","De Luca, Caterina","Iaccarino, Antonino","Pepe, Francesco","Pisapia, Pasquale","Russo, Maria","Sgariglia, Roberta","Nacchio, Mariantonia","Vigliar, Elena","Bellevicine, Claudio","Schmitt, Fernando C","Troncone, Giancarlo","32434770"],"abstract":["AIMS: In the time of COVID-19, predictive molecular pathology laboratories must still timely select oncological patients for targeted treatments. However, the need to respect social distancing measures may delay results generated by laboratory-developed tests based on sequential steps a long hands-on time. Laboratory workflows should now be simplified. METHODS: The organisation of the University of Naples Federico II predictive pathology laboratory was assessed before (March-April 2019) and during (March-April 2020) the Italian lockdown. RESULTS: The number of patients undergoing single or multiple biomarker testing was similar in 2019 (n=43) and in 2020 (n=45). Considering adequate samples for molecular testing, before the outbreak, next-generation sequencing was mostly used (35/42, 83.3%). Testing six genes had a reagent cost of euro98/patient. Conversely, in 2020, almost all cases (38/41, 92.7%) were analysed by automated testing. This latter had for any single assay/gene a significant reagent cost (euro95-euro136) and a faster mean turnaround time (5.3 vs 7.9 working days). CONCLUSION: In the times of coronavirus, laboratory fully automated platforms simplify predictive molecular testing. Laboratory staff may be more safely and cost-effectively managed."],"journal":"J Clin Pathol","authors":["Malapelle, Umberto","De Luca, Caterina","Iaccarino, Antonino","Pepe, Francesco","Pisapia, Pasquale","Russo, Maria","Sgariglia, Roberta","Nacchio, Mariantonia","Vigliar, Elena","Bellevicine, Claudio","Schmitt, Fernando C","Troncone, Giancarlo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434770","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jclinpath-2020-206711","keywords":["laboratory personnel","medical oncology","pathology, molecular"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1667521393637457923,"score":9.490897,"similar":[{"pmid":32312717,"title":"Cytology in the time of coronavirus disease (covid-19): an Italian perspective.","text":["Cytology in the time of coronavirus disease (covid-19): an Italian perspective.","INTRODUCTION: The coronavirus disease 2019 (covid-19) is changing the way we practice pathology, including fine needle aspiration (FNA) diagnostics. Although recommendations have been issued to prioritise patients at high oncological risk, postponing those with unsuspicious presentations, real world data have not been reported yet. METHODS: The percentages of the cytological sample types processed at the University of Naples Federico II, during the first 3 weeks of Italian national lockdown were compared with those of the same period in 2019. RESULTS: During the emergency, the percentage of cytology samples reported as malignant increased (p<0.001), reflecting higher percentages of breast (p=0.002) and lymph nodes FNAs (p=0.008), effusions (p<0.001) and urine (p=0.005). Conversely, thyroid FNAs (p<0.001) and Pap smears (p=0.003) were reduced. CONCLUSIONS: Even in times of covid-19 outbreak, cytological examination may be safely carried out in patients at high oncological risk, without the need to be postponed.","J Clin Pathol","Vigliar, Elena","Iaccarino, Antonino","Bruzzese, Dario","Malapelle, Umberto","Bellevicine, Claudio","Troncone, Giancarlo","32312717"],"abstract":["INTRODUCTION: The coronavirus disease 2019 (covid-19) is changing the way we practice pathology, including fine needle aspiration (FNA) diagnostics. Although recommendations have been issued to prioritise patients at high oncological risk, postponing those with unsuspicious presentations, real world data have not been reported yet. METHODS: The percentages of the cytological sample types processed at the University of Naples Federico II, during the first 3 weeks of Italian national lockdown were compared with those of the same period in 2019. RESULTS: During the emergency, the percentage of cytology samples reported as malignant increased (p<0.001), reflecting higher percentages of breast (p=0.002) and lymph nodes FNAs (p=0.008), effusions (p<0.001) and urine (p=0.005). Conversely, thyroid FNAs (p<0.001) and Pap smears (p=0.003) were reduced. CONCLUSIONS: Even in times of covid-19 outbreak, cytological examination may be safely carried out in patients at high oncological risk, without the need to be postponed."],"journal":"J Clin Pathol","authors":["Vigliar, Elena","Iaccarino, Antonino","Bruzzese, Dario","Malapelle, Umberto","Bellevicine, Claudio","Troncone, Giancarlo"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312717","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1136/jclinpath-2020-206614","keywords":["cytological techniques","health services","infection control","medical oncology","safety"],"locations":["Italian","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138493468803074,"score":286.39175},{"pmid":32353760,"pmcid":"PMC7195328","title":"Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","text":["Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2.","BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform.","J Clin Virol","Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A","32353760"],"abstract":["BACKGROUND: Numerous nucleic acid amplification assays have recently received emergency use authorization (EUA) for the diagnosis of SARS-CoV-2 infection, and there is a need to assess their test performance relative to one another. OBJECTIVES: The aim of this study was to compare the test performance of the Hologic Panther Fusion SARS-CoV-2 assay targeting two regions of open reading frame 1ab (ORF1ab) to a high complexity molecular-based, laboratory-developed EUA from Stanford Health Care (SHC) targeting the SARS-CoV-2 envelope (E) gene. STUDY DESIGN: We performed a diagnostic comparison study by testing nasopharyngeal samples on the two assays. Assay agreement was assessed by overall percent agreement and Cohen's kappa coefficient. RESULTS: A total of 184 nasopharyngeal samples were tested using the two assays, of which 180 showed valid results and were included for the comparative analysis. Overall percent agreement between the assays was 98.3 % (95 % confidence interval (CI) 95.2-99.7) and kappa coefficient was 0.97 (95 % CI 0.93-1.0). One sample was detected on the SHC laboratory developed test (LDT) and not on the Panther Fusion, and had a Ct of 35.9. Conversely, 2 samples were detected on the Panther Fusion and not on the LDT, and had Ct values of 37.2 and 36.6. CONCLUSION: The Panther Fusion SARS-CoV-2 assay and the SHC LDT perform similarly on clinical nasopharyngeal swab specimens. Other considerations, including reagent availability, turnaround time, labor requirements, cost and instrument throughput should guide the decision of which assay to perform."],"journal":"J Clin Virol","authors":["Hogan, Catherine A","Sahoo, Malaya K","Huang, ChunHong","Garamani, Natasha","Stevens, Bryan","Zehnder, James","Pinsky, Benjamin A"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353760","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jcv.2020.104383","keywords":["laboratory-developed test","panther fusion","qiasymphony","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495755747328,"score":243.96487},{"pmid":32388471,"title":"Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","text":["Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting.","J Clin Virol","Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc","32388471"],"abstract":["BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting."],"journal":"J Clin Virol","authors":["Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388471","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104390","keywords":["covid-19","neumodx","pcr","rapid testing","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892759457792,"score":205.8586},{"pmid":32335089,"pmcid":"PMC7179514","title":"Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","text":["Highly sensitive detection of SARS-CoV-2 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical laboratories.","BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians.","Clin Chim Acta","Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki","32335089"],"abstract":["BACKGROUND: The detection of SARS-CoV-2 RNA by real-time reverse transcription-polymerase chain reaction (rRT-PCR) is used to confirm the clinical diagnosis of COVID-19 by molecular diagnostic laboratories. We developed a multiplex rRT-PCR methodology for the detection of SARS-CoV-2 RNA. METHODS: Three genes were used for multiplex rRT-PCR: the Sarbecovirus specific E gene, the SARS-CoV-2 specific N gene, and the human ABL1 gene as an internal control. RESULTS: Good correlation of Cq values was observed between the simplex and multiplex rRT-PCR methodologies. Low copies (<25 copies/reaction) of SARS-CoV-2 RNA were detected by the novel multiplex rRT-PCR method. CONCLUSION: The proposed multiplex rRT-PCR methodology will enable highly sensitive detection of SARS-CoV-2 RNA, reducing reagent use and cost, and time required by clinical laboratory technicians."],"journal":"Clin Chim Acta","authors":["Ishige, Takayuki","Murata, Shota","Taniguchi, Toshibumi","Miyabe, Akiko","Kitamura, Kouichi","Kawasaki, Kenji","Nishimura, Motoi","Igari, Hidetoshi","Matsushita, Kazuyuki"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335089","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.cca.2020.04.023","keywords":["covid-19","high-sensitive","molecular diagnosis","multiplex","sars-cov-2","rrt-pcr"],"locations":["Sarbecovirus"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494101094400,"score":186.6711},{"pmid":32156329,"pmcid":"PMC7068162","title":"Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","text":["Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results.","Euro Surveill","Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc","32156329"],"abstract":["Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results."],"journal":"Euro Surveill","authors":["Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156329","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.2807/1560-7917.ES.2020.25.9.2000152","keywords":["covid-19","sars-cov-2","automation","high-throughput pcr","molecular diagnostic"],"link_comment_for":"31992387","topics":["Diagnosis"],"weight":1,"_version_":1666138492686565376,"score":181.67665}]}